Hua‐Jay J. Cherng

Columbia University Irving Medical Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL”.

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Blood Advances(2022)10.1182/bloodadvances.2022008174

N/A

0.629DataRank · unranked

15 citations

Stefan Alig, Yasuhiro Oki, Loretta J. Nastoupil, Luis Fayad, Sattva S. Neelapu +16 more

TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis

American Journal of Hematology(2022)10.1002/ajh.26595

N/A

0DataRank · unranked

14 citations

Raamis Khwaja, Rashmi Kanagal‐Shamanna, Guilin Tang, Jan A. Burger, Philip A. Thompson +10 more

Association of food insecurity and financial hardship with healthcare utilization among adults with cancer treated in a large, urban cancer center.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.e13579

N/A

0DataRank · unranked

0 citations

Claire Sathe, David DeStephano, Hua‐Jay J. Cherng, Justine M. Kahn, Jason D. Wright +3 more

854 | SEQUENCING‐GUIDED CHEMOTHERAPY OPTIMIZATION USING REAL‐TIME EVALUATION IN NEWLY DIAGNOSED DLBCL WITH CIRCULATING TUMOR DNA: SHORTEN‐ctDNA

Hematological Oncology(2025)10.1002/hon.70096_854

N/A

0DataRank · unranked

0 citations

S. Meek, Costin Leu, Beatriz Raposo Corradini, Seda S. Tolu, Jennifer E. Amengual +3 more